InsiderSignal.AI

InsiderSignal.ai

KLRA - Kailera Therapeutics, Inc.

Insider Purchase by Bain Capital Investors LLC (10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Bain Capital Investors LLC, serving as 10% owner at Kailera Therapeutics, Inc. (KLRA), purchased 8,398,438 shares at $16.00 per share, for a total transaction value of $134,375,008.00. Following this transaction, Bain Capital Investors LLC now holds 26,255,581 shares of KLRA.

This purchase represents a 47.00% increase in Bain Capital Investors LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 20, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, meaning the disclosure happened on the same day as the trade.

Kailera Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Bain Capital Investors LLC

Bain Capital Investors LLC

10%

Bain Capital is a global private investment firm founded in 1984 by Mitt Romney, T. Coleman Andrews III, and Eric Kriss[[1]](https://www.investmentnews.com/companies/bain-capital/257274). Based in Boston, Massachusetts, the firm manages approximately $185 billion in assets across 24 offices worldwide and employs over 1,750 people[[1]](https://www.investmentnews.com/companies/bain-capital/257274). Bain Capital pioneered the value-added investment approach and specializes across multiple asset classes including private equity, public equity, venture capital, credit, real estate, and impact investing, serving diverse sectors such as healthcare, technology, consumer products, financial services, and industrials[[1]](https://www.investmentnews.com/companies/bain-capital/257274)[[2]](https://www.baincapitalprivateequity.com/about-us). Under the leadership of co-managing partners John Connaughton and David Gross, alongside chair Jonathan Lavine, Bain Capital has established itself as one of the world's leading private investment firms[[1]](https://www.investmentnews.com/companies/bain-capital/257274). The firm has demonstrated its investment acumen through major transactions, including the $4.5 billion acquisition of Envestnet alongside partners BlackRock and Fidelity, and taking Chindata Group Holdings private in a $3.2 billion deal in 2023[[1]](https://www.investmentnews.com/companies/bain-capital/257274). In recent years, Bain Capital launched an ESG hedge fund focused on sustainable investments in 2021 and continues to expand its portfolio with strategic investments across multiple geographies and industries[[1]](https://www.investmentnews.com/companies/bain-capital/257274).

View full insider profile →

Trade Price

$16.00

Quantity

8,398,438

Total Value

$134,375,008.00

Shares Owned

26,255,581

Trade Date

Monday, April 20, 2026

1 days ago

SEC Filing Date

Monday, April 20, 2026

HEALTHCAREBIOTECHNOLOGY

About Kailera Therapeutics, Inc.

Company Overview

No company information available
View news mentioning KLRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5808543

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime